This performance underscores our ability to execute on multiple fronts while building for future growth. I'm excited to share that we achieved our largest sequential increase in referrals since launch. This meaningful sequential growth reflects the impact of our expanded team into the community setting, giving us confidence that we will continue to see benefits from our broadened physician reach. The momentum we are now driving gives us tremendous confidence in NUPLAZID's potential to unlock higher growth in the coming years.
The impact of this sales team expansion, combined with our direct-to-consumer campaigns, creates a powerful combination that we believe will drive sustained growth and value maximization for NUPLAZID. We're looking to build on our commercial success by advancing our pipeline of novel product candidates, including the recent initiation of one phase II and one phase III trials. DAYBUE sales were $101.1 million in Q3, representing our highest revenue and total prescription volume in any quarter to date since launch. Referrals are leading the way, with the highest quarter-over-quarter increase since DAYBUE's launch in 2023.
Supported by a similar increase in the number of educational programs we delivered, both of which are important levers in helping to educate prescribers on the benefits that DAYBUE has to offer. As we expand our reach beyond COEs, we see this segment as a significant growth driver for 2026 and beyond. The strength of these metrics is important, as they further reinforce not only our confidence in DAYBUE's therapeutic value, but also our outlook for sustainable long-term growth in the U.S. Looking ahead, we remain confident in DAYBUE's growth outlook, driven by sustained demand generation supported by our strategic field force investments, strong persistency metrics, and expanding global access.
| Metric | Period | Current guidance |
|---|---|---|
| NUPLAZID net sales | FY2025 | $685M-$695M (raised) |
| DAYBUE net sales | FY2025 | $385M-$400M (now includes named patient supply programs) |
| R&D expense | FY2025 | $335M-$345M |
| SG&A expense | FY2025 | $540M-$555M |
| Total revenue | FY2025 | On track to exceed $1 billion for the first time in company history |
| Metric | YoY | Note |
|---|---|---|
| Total revenue | +11% | Broad-based strength across NUPLAZID and DAYBUE. |
| NUPLAZID net sales | +12% (9% volume) | Record quarter; new prescriptions +23% YoY (strongest since 2019) and referrals +21% as awareness and earlier treatment of Parkinson's disease psychosis improved. |
| DAYBUE net sales | +11% (all volume) | Highest quarter since launch; >1,000 unique patients globally, community physicians 74% of new Rx, and contributions from ex-U.S. named patient supply programs. |
| R&D expense | $87.8M vs $66.6M | Higher clinical trial spend on ACP-204, LBDP and ACP-101 plus personnel, partly offset by completed programs. |
| SG&A expense | $133.4M (roughly flat) | Essentially flat with the prior-year quarter. |
| Cash and investments | $847M (up from $762M in Q2) | Strong operating cash generation from the commercial portfolio. |
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| NUPLAZID field-force expansion | Reach-and-frequency model with DTC campaigns | Announced a 30% increase in the customer-facing team starting Q1 2026 to reach newly activated prescribers (including primary care, NPs and PAs) and improve pull-through; ~26% of Q3 prescriptions came from new writers. | — |
| DAYBUE community expansion | Field-force expansion earlier in 2025 | Community physicians drove 74% of new prescriptions and referrals hit their highest level since launch, with benefits expected to accelerate through Q4 and into 2026. | — |
| Pipeline cadence | Eight disclosed programs | Initiated Phase II ACP-204 (LBDP) and Phase III trofinetide (Japan); next up ACP-211 in MDD (Q4 2025) and first-in-human ACP-271 (GPR88 agonist) in Q1 2026; four Phase II/III readouts expected across 2026-2027, led by ACP-204 in Alzheimer's disease psychosis in mid-2026. | — |